Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) is now available.
Lumos Diagnostics Holdings Ltd., an ASX-listed diagnostics company trading under the ticker LDX, has moved to expand its capital base through the issuance of additional ordinary fully paid shares. The company operates in the healthcare diagnostics space and accesses public equity markets to fund and grow its operations.
The company has applied for quotation of 88,888,876 new ordinary fully paid shares on the ASX, with an issue date of 9 April 2026. This sizeable new share listing is part of previously announced transactions and is expected to increase the company’s free float and liquidity, with potential implications for existing shareholders’ dilution and market trading dynamics.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd. is a healthcare company listed on the ASX under the code LDX, operating in the diagnostics sector. The company issues ordinary fully paid shares and targets investors in the public capital markets to support its diagnostics-focused activities.
Average Trading Volume: 4,421,380
Technical Sentiment Signal: Buy
Current Market Cap: A$168.6M
See more insights into LDX stock on TipRanks’ Stock Analysis page.